share_log

Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $38

Benzinga ·  Mar 16, 2023 07:46

Credit Suisse analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Outperform and lowers the price target from $40 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment